Apexigen (NASDAQ:APGN) reported quarterly losses of $(0.41) per share which missed the analyst consensus estimate of $(0.38) by 7.89 percent.
With New Phase 3 Data From Its Hemophilia Study, Novo Nordisk Plots Route To FDA
Novo Nordisk A/S (NYSE:NVO) announced the phase 3 results of the explorer7 study, assessing the efficacy and safety of prophylactic treatment…